📰 Additional Condition News
Additional Condition News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Additional Condition. Real-time updates on events, politics, business and more.
April 2, 2024
02.04.2024 - Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant ... Seite 1
January 24, 2024
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review ...
January 24, 2024
FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development pr...
January 17, 2024
Petros Pharmaceuticals Demonstrates Positive Results Following Successful ...
April 24, 2023
The crucial role of self-care pharmacy practice requires that pharmacists develop a robust understanding of the implications of the current and proposed regulatory changes for nonprescription drugs.
January 16, 2023
2022 was a big year for the pharmaceutical and biotechnology sectors. Novel technologies emerged at a rapid clip. The Food and Drug Administration (“FDA” or the “Agency”) approved over...
December 16, 2022
The U.S. Food and Drug Administration (FDA) recently issued the Federal Register notice “Safety and Effectiveness of Certain Naloxone Hydrochloride Drug Products for Nonprescription...
November 29, 2022
NCPA submitted comments to FDA’s proposed rule, Nonprescription Drug Product With an Additional Condition for Nonprescription Use. According to the proposed rule, under an ACNU, a drug manufacturer must ensure that patients can appropriately self-select a medication.
September 29, 2022
In support of the American Telemedicine Association's Telehealth Awareness Week (September 18-24, 2022), Jones Day's Digital Health team shared key insights on various legal topics...
September 27, 2022
NCPA joined APhA, ASCP, NASP and NACDS in signing onto a letter calling for FDA to extend the comment deadline for the Nonprescription Drug Product With an Additional Condition for Nonprescription Use proposed rule by at least 90 days to allow stakeholders to appropriately respond. Since comments are due Oct. 26, the extension, if granted, would allow comments to be submitted until about Jan. 26.